ATOMIC Trial Supports Atezolizumab Plus FOLFOX as the New Standard in dMMR Stage Colon Cancer скачать в хорошем качестве

ATOMIC Trial Supports Atezolizumab Plus FOLFOX as the New Standard in dMMR Stage Colon Cancer

Dr. David J. Kerr discusses the results of the groundbreaking ATOMIC trial, which investigated the use of immunotherapy in stage III colon cancer. He examines the study's findings, highlighting the potential for practice-changing outcomes in patients with mismatch repair deficient (dMMR) tumors. Learn about the new data and the critical questions that still need to be addressed regarding treatment duration, toxicity, and cost-effectiveness. This video is a must-watch for oncologists and healthcare professionals interested in the latest advancements in colorectal cancer treatment. #ColorectalCancer #Oncology #Immunotherapy #ATOMICtrial #CancerResearch #ClinicalTrial #dMMR #ColonCancer #MedicalEducation #ASCO 00:00 - Introduction to the ATOMIC Trial 00:19 - Overview of the ATOMIC Study Design 00:54 - Key Patient Inclusion Criteria 01:34 - Primary Outcome: Disease-Free Survival 02:44 - Is this a New Standard of Care? 03:10 - Remaining Questions on Duration and Toxicity 04:09 - The Future of dMMR Colon Cancer Treatment 04:30 - Final Thoughts and Call for Comments For transcript, references and more visit: https://www.medscape.com/viewarticle/...